Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocin-induced diabetes

Journal of Pharmacological Sciences

Volumn 110, Issue 4, 2009, Pages 459-465

  Takai, Shinji ^a   Jin, Denan ^a   Ohzu, Mariko ^a   Tanaka, Kazuhiko ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Chymase; Diabetes; Inhibitor; Pancreas

Indexed keywords

ANGIOTENSIN II; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; MALONALDEHYDE; PLACEBO; TY 51469; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL PROTECTION; CONTROLLED STUDY; DISORIENTATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HAMSTER; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; STREPTOZOCIN DIABETES;

ANGIOTENSIN II; ANIMALS; BLOOD GLUCOSE; CHYMASES; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; ISLETS OF LANGERHANS; MALE; MALONDIALDEHYDE; PEPTIDYL-DIPEPTIDASE A; STREPTOZOCIN; SULFONAMIDES; THIOPHENES; TIME FACTORS;

EID: 68849084078     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09115FP     Document Type: Article

References (24)

1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
3. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al. For the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879-1886. (Pubitemid 35041980)
4. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes. 1999;107:133-139. (Pubitemid 29179280)
5. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 2001;38:884-890. (Pubitemid 34258687)
6. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia. 1998;41:127-133. (Pubitemid 28088387)
7. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol. 1999;161:317-322. (Pubitemid 29244259)
8. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes. 2004;53:989-997. (Pubitemid 38436611)
9. Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes. 2003;52:1457-1463. (Pubitemid 36666201)
10. 2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int J Biochem Cell Biol. 2004;36:330-339.
11. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is up-regulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14:1738-1747.
12. Yamamoto D, Shiota N, Takai S, Ishida T, Okunishi H, Miyazaki M. Three-dimensional molecular modeling explains why catalytic function for angiotensin-I is different between human and rat chymases. Biochem Biophys Res Commun. 1998;242:158-163. (Pubitemid 28412395)
13. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta. 2001;305:191-195. (Pubitemid 32201977)
14. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 1996;58:591-597. (Pubitemid 26046951)
15. Palaniyandi SS, Nagai Y, Watanabe K, Ma M, Veeraveedu PT, Prakash P, et al. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med. 2007;232:1213-1221. (Pubitemid 47503062)
16. Povoski SP, McCullough PJ, Zhou W, Bell RH Jr. Induction of diabetes mellitus in Syrian golden hamsters using stored equilibrium solutions of streptozotocin. Lab Anim Sci. 1993; 43:310-314. (Pubitemid 23354223)
17. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, et al. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2- ethoxy-benzyl)-4-oxoazetidine- 2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther. 2003;305:17-23. (Pubitemid 36373831)
18. Fukuda K, Tesch GH, Nikolic-Paterson DJ. c-Jun amino terminal kinase 1 deficient mice are protected from streptozotoc-ininduced islet injury. Biochem Biophys Res Commun. 2008;366:710-716.
19. Okamoto H. The role of poly(ADP-ribose) synthetase in the development of insulin-dependent diabetes and islet β-cell regeneration. Biomed Biochim Acta. 1985;44:15-20. (Pubitemid 15100858)
20. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 1998;32:514-520. (Pubitemid 28429142)
21. Longley BJ, Tyrrell L, Ma Y, Williams DA, Halaban R, Langley K, et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci U S A. 1997;94:9017-9021. (Pubitemid 27357774)
22. Tsunemi K, Takai S, Nishimoto M, Jin D, Sakaguchi M, Muramatsu M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6- dihydropyrimidine-1-yl)-N-[[3,4-ioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl] acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther. 2004;309:879-883.
23. Maruichi M, Takai S, Sugiyama T, Ueki M, Oku H, Sakaguchi M, et al. Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in a canine conjunctival flap model. Exp Eye Res. 2004;79:111-118. (Pubitemid 38737388)
24. Ip SP, Tsang SW, Wong TP, Che CT, Leung PS. Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis. Pancreas. 2003;26:224-229.